The American journal of gastroenterology
-
Am. J. Gastroenterol. · Mar 2008
Randomized Controlled Trial Comparative StudyWarm water or oil-assisted colonoscopy: toward simpler examinations?
Completion rates, pain, and difficulties during the exam are still problems in colonoscopy. New methods of lubrication, rarely considered a matter of study, may help in this respect. Our aim was to compare an oil-assisted technique with a modified warm water method applied during colonoscopy. ⋯ Warm water and oil-assisted colonoscopy could be simple, safe, and inexpensive methods for easier and less painful examinations.
-
Am. J. Gastroenterol. · Jan 2008
Randomized Controlled Trial Multicenter Study Comparative StudyMulticenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.
To assess the efficacy and safety of lubiprostone in adults with chronic constipation. ⋯ In patients with chronic constipation, treatment with lubiprostone produces a BM in the majority of individuals within 24-48 h of initial dosing and improves the frequency as well as other characteristics associated with BMs with short-term (i.e., 4 wk) treatment. The most commonly reported adverse event was mild to moderate nausea, which resulted in treatment discontinuation in 5% of treated patients.
-
Am. J. Gastroenterol. · Jan 2008
Randomized Controlled Trial Comparative StudyPreoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial.
Helicobacter pylori (H. pylori) eradication is strongly recommended for gastric cancer patients who undergo subtotal gastrectomy. The efficacy of proton pump inhibitor-based triple therapy for H. pylori eradication has not been adequately assessed in the gastric remnant. The aim of this study was to compare the efficacy of postoperative versus preoperative H. pylori eradication therapy. ⋯ In distal gastric cancer patients, the effect of proton pump inhibitor-based triple therapy for H. pylori eradication was not different whether given postoperatively or preoperatively.
-
Am. J. Gastroenterol. · Dec 2007
Randomized Controlled TrialA pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
Forty-eight weeks of peginterferon alfa-2a is the approved regimen for chronic hepatitis B (CHB). Standard interferon is more effective for hepatitis B e antigen (HBeAg)-negative CHB when given for longer than 1 yr. This study evaluated peginterferon alfa-2a for 60 wk, alone or in combination with lamivudine. ⋯ Sixty weeks of peginterferon alfa-2a with or without lamivudine resulted in a higher rate of SVR compared to historical controls with HBeAg-negative CHB treated with 48 wk of pegylated interferon. Larger studies are necessary to assess if longer duration therapy is more effective than the standard regimen and results in a greater decline in HBsAg concentration.
-
Am. J. Gastroenterol. · Sep 2007
Randomized Controlled Trial Multicenter Study Comparative StudyA randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation.
Polyethylene glycol (PEG) 3350 (MiraLax) and tegaserod (Zelnorm), a serotonin subtype 4 receptor partial agonist, are currently approved for treatment of constipation. This study was designed to compare the efficacy of each product over a 4-wk treatment period. ⋯ While PEG laxative and tegaserod are safe for their intended use in chronic constipation, PEG had superior efficacy, caused fewer headaches, and produced greater improvement of constipation symptoms.